The company is planning to test higher doses of the drug. Gilead Fends Off Criticism for Lenacapavir Access Program ... Both assets are poised to enter registrational studies under accelerated ...

The declines began with the pandemic, well before routine vaccines became part of the national political conversation. By Francesca Paris After years of holding steady, American vaccination rates ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare ...

The FDA identified an estimated 9 excess GBS cases per million doses for Pfizer's Abrysvo and 7 excess cases per million for GSK's Arexvy. Updated warnings stem from Medicare-based studies ...

GSK Plc and Pfizer Inc. ’s vaccines for a common respiratory virus must carry warnings that they may be tied to an increased risk of a rare neurological side effect that can lead to paralysis, the US ...

has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal polyps (CRSwNP) in the adult population. This marks the ...

The unidentified “healthy young woman” reportedly started experiencing the rapid growth one week after getting vaccinated in September 2022 — and it worsened after her second dose. “The patient ...

London: GSK plc has announced that the China National Medical Products Administration has ... It is estimated that about 107 million people in China suffer from chronic sinusitis, about 1/3 of whom ...

GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...

It is estimated that about 107 million people in China suffer from chronic sinusitis, about 1/3 of whom have chronic sinusitis with nasal polyps. Also Read: GSK Raises Prospects For Withdrawn ...

It said CRSwNP, a condition marked by chronic inflammation and the growth of nasal polyps ... Japan, and Russia. GSK said those findings were complemented by results from the global SYNAPSE ...